PMID- 29100708
OWN - NLM
STAT- MEDLINE
DCOM- 20180704
LR  - 20180704
IS  - 1873-2518 (Electronic)
IS  - 0264-410X (Linking)
VI  - 35
IP  - 50
DP  - 2017 Dec 15
TI  - Safety and immune response after two-dose meningococcal C conjugate immunization 
      in HIV-infected children and adolescents in Rio de Janeiro, Brazil.
PG  - 7042-7048
LID - S0264-410X(17)31451-2 [pii]
LID - 10.1016/j.vaccine.2017.10.043 [doi]
AB  - We aimed to evaluate immunogenicity and adverse events (AEs) after a booster dose 
      of Meningococcal C conjugated (MCC) vaccine in HIV-infected children and 
      adolescents, who had a previous low seroconversion rate after priming with MCC, 
      at a reference HIV-care center in Rio de Janeiro. METHODS: 2-18 years old 
      HIV-infected subjects with CD4+ T-lymphocyte cell (CD4) >/=15%, without active 
      infection or antibiotic use, were enrolled to receive 2 doses of conjugated 
      meningococcal C oligosaccharide-CRM197 12-18 months apart. All patients were 
      evaluated before and 1-2 months after immunization for seroprotection [defined as 
      human serum bactericidal activity (hSBA) titer >/=1:4]. AEs were assessed at 
      20 min, 3 and 7 days after each dose. Factors independently associated with 
      seroprotection were studied. RESULTS: 156 subjects were enrolled and 137 received 
      a booster MCC dose. 55% were female, and median age was 12 years. Eight-nine 
      percent were receiving combined antiretroviral therapy (cART) at the booster 
      visit (median duration of 7.7 years), 59.9% had undetectable viral load (VL) at 
      baseline, and 56.2% at the booster visit. Seroprotection was achieved in 78.8% 
      (108/137) subjects, with a significantly higher GMT than after the priming dose 
      (p < 0.01). Mild AEs were experienced after a second MCC dose (38%). In logistic 
      regression, undetectable viral load at entry [odds ratio (OR) = 7.1, 95% 
      confidence interval (95%CI): 2.14-23.37], and probably higher CD4 percent at the 
      booster immunization visit (OR): 1.1, 95%CI: 1.01-1.17 were associated with 
      seroprotection after a booster dose of MCC. CONCLUSION: A booster dose of MCC was 
      safe and induced high seroprotection rate even 12-18 months after priming. MCC 
      should be administered after maximum virologic suppression has been achieved. 
      These results support the recommendation of 2-dose of MCC for primary 
      immunization in HIV-infected children and adolescents with restored immune 
      function.
CI  - Copyright (c) 2017 Elsevier Ltd. All rights reserved.
FAU - Frota, Ana Cristina C
AU  - Frota ACC
AD  - Preventive Medicine Department, School of Medicine, Federal University of Rio de 
      Janeiro, Rio de Janeiro, Brazil. Electronic address: anacfrota@gmail.com.
FAU - Ferreira, Bianca
AU  - Ferreira B
AD  - Preventive Medicine Department, School of Medicine, Federal University of Rio de 
      Janeiro, Rio de Janeiro, Brazil.
FAU - Harrison, Lee H
AU  - Harrison LH
AD  - University of Pittsburgh, Pittsburgh, EUA, United States.
FAU - Pereira, Gisele S
AU  - Pereira GS
AD  - State University of Rio de Janeiro, Department of Microbiology, Immunology and 
      Parasitology, Rio de Janeiro, Brazil.
FAU - Pereira-Manfro, Wania
AU  - Pereira-Manfro W
AD  - State University of Rio de Janeiro, Department of Microbiology, Immunology and 
      Parasitology, Rio de Janeiro, Brazil.
FAU - Machado, Elizabeth S
AU  - Machado ES
AD  - Preventive Medicine Department, School of Medicine, Federal University of Rio de 
      Janeiro, Rio de Janeiro, Brazil.
FAU - de Oliveira, Ricardo Hugo
AU  - de Oliveira RH
AD  - Instituto de Puericultura e Pediatria Martagao Gesteira, Federal University of 
      Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Abreu, Thalita F
AU  - Abreu TF
AD  - Instituto de Puericultura e Pediatria Martagao Gesteira, Federal University of 
      Rio de Janeiro, Rio de Janeiro, Brazil.
FAU - Milagres, Lucimar G
AU  - Milagres LG
AD  - State University of Rio de Janeiro, Department of Microbiology, Immunology and 
      Parasitology, Rio de Janeiro, Brazil.
FAU - Hofer, Cristina B
AU  - Hofer CB
AD  - Preventive Medicine Department, School of Medicine, Federal University of Rio de 
      Janeiro, Rio de Janeiro, Brazil.
LA  - eng
GR  - R01 TW008397/TW/FIC NIH HHS/United States
GR  - D43 TW006592/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20171031
PL  - Netherlands
TA  - Vaccine
JT  - Vaccine
JID - 8406899
RN  - 0 (MenC-CRM vaccine)
RN  - 0 (Meningococcal Vaccines)
SB  - IM
MH  - Adolescent
MH  - *Blood Bactericidal Activity
MH  - Brazil
MH  - Child
MH  - Child, Preschool
MH  - Drug-Related Side Effects and Adverse Reactions/*epidemiology/pathology
MH  - Female
MH  - HIV Infections/*complications
MH  - Humans
MH  - Immunization, Secondary/*adverse effects
MH  - Male
MH  - Meningococcal Infections/*prevention & control
MH  - Meningococcal Vaccines/administration & dosage/*adverse effects/*immunology
MH  - Surveys and Questionnaires
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Brazil
OT  - Children
OT  - HIV
OT  - Meningococcal vaccine/adverse effects
OT  - Meningococcal vaccine/immunology
EDAT- 2017/11/05 06:00
MHDA- 2018/07/05 06:00
CRDT- 2017/11/05 06:00
PHST- 2017/07/03 00:00 [received]
PHST- 2017/10/12 00:00 [revised]
PHST- 2017/10/13 00:00 [accepted]
PHST- 2017/11/05 06:00 [pubmed]
PHST- 2018/07/05 06:00 [medline]
PHST- 2017/11/05 06:00 [entrez]
AID - S0264-410X(17)31451-2 [pii]
AID - 10.1016/j.vaccine.2017.10.043 [doi]
PST - ppublish
SO  - Vaccine. 2017 Dec 15;35(50):7042-7048. doi: 10.1016/j.vaccine.2017.10.043. Epub 
      2017 Oct 31.